We will fight for you and have your back no matter what. Join the tens of thousands of people we’ve helped.

36 +
Years
$1 B+
DOLLARS
500 +
clients
20
experts

Cases

Search for a case

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Cases

February 9, 2023

Sumo Logic, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Sumo Logic, Inc. (“Sumo” or the “Company”) (NASDAQ:SUMO), in connection with the proposed acquisition of the Company by affiliates of Francisco Partners. Under the terms of the merger agreement, the Company’s shareholders will receive $12.05 in cash for each share of Sumo common stock owned.

Join Case →

February 9, 2023

Cardiovascular Systems, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cardiovascular Systems, Inc. (“Cardiovascular Systems” or the “Company”) (NASDAQ: CSII), in connection with the proposed acquisition of the Company by Abbott Laboratories (NYSE: ABT). Under the terms of the merger agreement, the Company’s shareholders will receive $20.00 in cash for each share of Cardiovascular Systems owned.

Join Case →

February 8, 2023

Argo Group International Holdings, Ltd. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Argo Group International Holdings, Ltd. (“Argo” or the “Company”) (NYSE: ARGO), in connection with the proposed acquisition of the Company by Brookfield Reinsurance Ltd. (NYSE: BNRE). Under the terms of the merger agreement, the Company’s shareholders will receive $30.00 in cash for each share of Argo common share owned.

Join Case →

February 8, 2023

Oak Street Health, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Oak Street Health, Inc. (“Oak Street” or the “Company”) (NYSE: OSH), in connection with the proposed acquisition of the Company by CVS Health Corporation (NYSE: CVS). Under the terms of the merger agreement, the Company’s shareholders will receive $39.00 in cash for each share of Oak Street common stock owned.

Join Case →

February 6, 2023

AlerisLife Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of AlerisLife Inc. (“AlerisLife” or the “Company”) (NASDAQ:ALR) in connection with the proposed acquisition of the Company by ABP Acquisition LLC via tender offer. Under the terms of the merger agreement, the Company’s shareholders will receive $1.31 in cash for each share of AlerisLife common stock owned.

Join Case →

February 3, 2023

IsoPlexis Corporation Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of IsoPlexis Corporation (“IsoPlexis” or the “Company”) (NASDAQ: ISO) in connection with its proposed acquisition by Berkeley Lights, Inc. (“Berkeley Lights”) (NASDAQ: BLI). Under the merger agreement, the Company’s shareholders will receive 0.612 shares of Berkeley Lights common stock for each IsoPlexis share, representing implied per-share consideration of $1.44 based upon Berkeley Lights’ February 2, 2023 closing price of $2.36.

Join Case →

January 31, 2023

Atlas Technical Consultants, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Atlas Technical Consultants, Inc. (“Atlas” or the “Company”) (NASDAQ: ATCX), in connection with the proposed acquisition of the Company by GI Partners. Under the terms of the merger agreement, the Company’s shareholders will receive $12.25 in cash for each share of Atlas common stock owned.

Join Case →

January 23, 2023

Evoqua Water Technologies Corp. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Evoqua Water Technologies Corp. (“Evoqua” or the “Company”) (NYSE: AQUA) in connection with the proposed acquisition of the Company by Xylem Inc. (“Xylem”) (NYSE: XYL). Under the merger agreement, the Company’s shareholders will receive 0.480 shares of Xylem common stock for each Evoqua share, representing implied per-share consideration of $52.89 based upon Xylem’s January 20, 2023 closing price of $110.18.

Join Case →

January 19, 2023

Concert Pharmaceuticals, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Concert Pharmaceuticals, Inc. (“Concert” or the “Company”) (NASDAQ: CNCE), in connection with the proposed acquisition of the Company by Sun Pharmaceutical Industries Limited via tender offer. Under the terms of the merger agreement, the Company’s shareholders will receive $8.00 in cash for each share of Concert common stock owned, plus one non-tradeable contingent value right (“CVR”) per share.

Join Case →

Where to find us?

new york

305 Broadway, 7th FI
New York, NY 10007
(212) 682-3025

california

8383 Wilshire Blvd., Suite 935
Beverly Hills, CA 90211
(310) 208-2800

georgia

476 Hardendorf Ave. NE
Atlanta, GA 30307
(404) 692-7910

NEW JERSEY

4 Brighton Rd, Suite. 204
Clifton, NJ 07012

Copyright 2022 Weiss Law. All rights reserved

Attorney AdvertisingLegal

Design by Cramdyn